骨髓增殖性肿瘤慢性期低负荷TP53突变与年龄、羟基脲使用、疾病类型及JAK2突变状态的关联
采用超深度二代测序检测254例接受羟基脲、干扰素α-2a或阿那格雷治疗的MPN患者及85例未治疗患者,50例检出TP53突变(VAF 0.2-16.3%),与疾病亚型、驱动基因状态及细胞减灭治疗无关;年龄是低负荷TP53突变发生的最强影响因素,未发现TP53突变与羟基脲存在年龄非依赖性显著关联,突变可低水平持续多年而无立即进展风险。
要点
- 年龄是低负荷TP53突变发生的最强影响因素,治疗与TP53突变均与高龄强相关。
- 未发现TP53突变与羟基脲存在年龄非依赖性显著关联,突变可低水平持续多年无立即进展风险。
核心结论
- 患者年龄是影响MPN低负荷TP53突变发生的最强因素,未发现TP53突变与羟基脲之间存在年龄非依赖性显著关联。
- TP53突变可以低水平持续多年而无立即进展风险。
研究设计与样本
- 采用超深度二代测序检测254例接受羟基脲、干扰素α-2a或阿那格雷治疗的MPN患者和85例未治疗患者。
主要发现
- 50例检出TP53突变,VAF为0.2-16.3%,与疾病亚型、驱动基因状态及细胞减灭治疗无关。
- 治疗与TP53突变均与高龄强相关。
- 纵向分析显示突变在诊断时可能不可测,并在病程中缓慢增加。
- 尽管3例TP53突变患者进展为TP53突变型或TP53野生型AML,随访期间未观察到对总生存的年龄非依赖性显著影响。
- 单独完全p53失活既未导致原始细胞转化,也未导致羟基脲耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2-16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.
引用
- Kubesova B, Pavlova S, Malcikova J, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2017. PMID: 28744014. doi:10.1038/leu.2017.230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。